95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Niu Ping1Kuiyang Zuo2Jiahan Cai3Chunshu Rong1Ziqiao Yu4Xu Zhang2Gaihua Wang2Chunyu Ma1Huirong Yang1
Jinhua Li2*
Xu Wang1,2,4*Dexi Zhao4*- 1Department of Encephalopathy, Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, China
- 2School of Public Health, Jilin University, Changchun, Jilin, China
- 3Traditional Chinese Medicine College, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
- 4College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China
A Corrigendum on
Apigenin protects against ischemic stroke by increasing DNA repair
by Ping N, Zuo K, Cai J, Rong C, Yu Z, Zhang X, Wang G, Ma C, Yang H, Li J, Wang X and Zhao D (2024). Front. Pharmacol. 15:1362301. doi: 10.3389/fphar.2024.1362301
In the published article, there was an error in the author list. The footnote “†These authors have contributed equally to this work” was erroneously included in relation to the authors Ping Niu and Kuiyang Zuo. The corrected author list appears above.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Apigenin, ischemic stroke, parthanatos, homologous recombination repair, non-homologous end link repair
Citation: Ping N, Zuo K, Cai J, Rong C, Yu Z, Zhang X, Wang G, Ma C, Yang H, Li J, Wang X and Zhao D (2025) Corrigendum: Apigenin protects against ischemic stroke by increasing DNA repair. Front. Pharmacol. 16:1562125. doi: 10.3389/fphar.2025.1562125
Received: 17 January 2025; Accepted: 04 February 2025;
Published: 17 February 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Ping, Zuo, Cai, Rong, Yu, Zhang, Wang, Ma, Yang, Li, Wang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dexi Zhao, emR4MDJAMTYzLmNvbQ==; Xu Wang, MjAyMDI3MDExNjRAc3R1LmNjdWNtLmVkdS5jbg==; Jinhua Li, amluaHVhMUBqbHUuZWR1LmNu